TNF and Vogt-Koyanagi-Harada disease: TNF-α inhibition with ADA—often used in combination with conventional immunomodulators—appears to be an effective and safe therapeutic option for managing inflammation, reducing corticosteroid burden, and decreasing relapse frequency in patients with chronic recurrent VKH disease refractory to conventional treatments.